YO-2

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 465001

CAS#: 288254-44-4 (free base)

Description: YO-2 is a selective plasmin inhibitor. YO-2 induces thymocyte apoptosis via activation of caspase cascade.

Chemical Structure

img
YO-2
CAS# 288254-44-4 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 465001
Name: YO-2
CAS#: 288254-44-4 (free base)
Chemical Formula: C31H46N4O3
Exact Mass: 522.36
Molecular Weight: 522.730
Elemental Analysis: C, 71.23; H, 8.87; N, 10.72; O, 9.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 325463-91-0 (HCl)   288254-44-4 (free base)    

Synonym: YO-2; YO 2; YO2;

IUPAC/Chemical Name: (1r,4S)-4-(aminomethyl)-N-((S)-1-(octylamino)-1-oxo-3-(4-(pyridin-4-ylmethoxy)phenyl)propan-2-yl)cyclohexane-1-carboxamide

InChi Key: ZBCXDUNUUKRQSV-RWPDHJIBSA-N

InChi Code: InChI=1S/C31H46N4O3/c1-2-3-4-5-6-7-18-34-31(37)29(35-30(36)27-12-8-25(22-32)9-13-27)21-24-10-14-28(15-11-24)38-23-26-16-19-33-20-17-26/h10-11,14-17,19-20,25,27,29H,2-9,12-13,18,21-23,32H2,1H3,(H,34,37)(H,35,36)/t25-,27-,29-/m0/s1

SMILES Code: CCCCCCCCNC([C@@H](NC([C@@H]1CC[C@H](CC1)CN)=O)CC2=CC=C(C=C2)OCC3=CC=NC=C3)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 522.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Schlottmann F, Strassle PD, Nayyar A, Herbella FAM, Cairns BA, Patti MG. Postoperative outcomes of esophagectomy for cancer in elderly patients. J Surg Res. 2018 Sep;229:9-14. doi: 10.1016/j.jss.2018.03.050. Epub 2018 Apr 16. PubMed PMID: 29937021.

2: Eiamboonsert S, Salama Y, Watarai H, Dhahri D, Tsuda Y, Okada Y, Hattori K, Heissig B. The role of plasmin in the pathogenesis of murine multiple myeloma. Biochem Biophys Res Commun. 2017 Jun 24;488(2):387-392. doi: 10.1016/j.bbrc.2017.05.062. Epub 2017 May 10. PubMed PMID: 28501622.

3: Cembrowski GS, Xu Q, Cembrowski AR, Mei J, Sadrzadeh H. Impaired clinical utility of sequential patient GEM blood gas measurements associated with calibration schedule. Clin Biochem. 2017 Nov;50(16-17):936-941. doi: 10.1016/j.clinbiochem.2017.03.014. Epub 2017 Mar 18. PubMed PMID: 28322757.

4: Ciodaro F, Cammaroto G, Galletti B, Galletti F. Subannular T-tubes for the treatment of adhesive otitis: how we do it. B-ENT. 2016 Aug;12(2):131-135. PubMed PMID: 29553618.

5: Hidaka K, Gohda K, Teno N, Wanaka K, Tsuda Y. Active site-directed plasmin inhibitors: Extension on the P2 residue. Bioorg Med Chem. 2016 Feb 15;24(4):545-53. doi: 10.1016/j.bmc.2015.12.009. Epub 2015 Dec 8. PubMed PMID: 26732532.

6: Xu Y, Furutani S, Ihara M, Ling Y, Yang X, Kai K, Hayashi H, Matsuda K. Meroterpenoid Chrodrimanins Are Selective and Potent Blockers of Insect GABA-Gated Chloride Channels. PLoS One. 2015 Apr 22;10(4):e0122629. doi: 10.1371/journal.pone.0122629. eCollection 2015. PubMed PMID: 25902139; PubMed Central PMCID: PMC4406737.

7: Munakata S, Tashiro Y, Nishida C, Sato A, Komiyama H, Shimazu H, Dhahri D, Salama Y, Eiamboonsert S, Takeda K, Yagita H, Tsuda Y, Okada Y, Nakauchi H, Sakamoto K, Heissig B, Hattori K. Inhibition of plasmin protects against colitis in mice by suppressing matrix metalloproteinase 9-mediated cytokine release from myeloid cells. Gastroenterology. 2015 Mar;148(3):565-578.e4. doi: 10.1053/j.gastro.2014.12.001. Epub 2014 Dec 6. PubMed PMID: 25490065.

8: Al-Horani RA, Desai UR. Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders. Med Res Rev. 2014 Nov;34(6):1168-216. doi: 10.1002/med.21315. Epub 2014 Mar 21. Review. PubMed PMID: 24659483.

9: Saraya A, Mahavihakanont A, Shuangshoti S, Sittidetboripat N, Deesudchit T, Callahan M, Wacharapluesadee S, Wilde H, Hemachudha T. Autoimmune causes of encephalitis syndrome in Thailand: prospective study of 103 patients. BMC Neurol. 2013 Oct 20;13:150. doi: 10.1186/1471-2377-13-150. PubMed PMID: 24139084; PubMed Central PMCID: PMC3853593.

10: Hayashi H, Oka Y, Kai K, Akiyama K. New chrodrimanin congeners, chrodrimanins D-H, from YO-2 of Talaromyces sp. Biosci Biotechnol Biochem. 2012;76(9):1765-8. Epub 2012 Sep 7. PubMed PMID: 22972343.

11: Hayashi H, Oka Y, Kai K, Akiyama K. A new meroterpenoid, chrodrimanin C, from YO-2 of Talaromyces sp. Biosci Biotechnol Biochem. 2012;76(4):745-8. Epub 2012 Apr 7. PubMed PMID: 22484942.

12: Gohda K, Teno N, Wanaka K, Tsuda Y. Predicting subsite interactions of plasmin with substrates and inhibitors through computational docking analysis. J Enzyme Inhib Med Chem. 2012 Aug;27(4):571-7. doi: 10.3109/14756366.2011.603129. Epub 2011 Oct 12. PubMed PMID: 21992704.

13: Okada Y. [Overview in 45 years of studies on peptide chemistry]. Yakugaku Zasshi. 2009 Oct;129(10):1141-54. Review. Japanese. PubMed PMID: 19797870.

14: Enomoto R, Sugahara C, Tsuda Y, Okada Y, Lee E. Thymocyte apoptosis induced by various compounds including YO-2 is accompanied by a change in chromatin structure. Ann N Y Acad Sci. 2004 Dec;1030:622-6. PubMed PMID: 15659845.

15: Enomoto R, Sugahara C, Komai T, Suzuki C, Kinoshita N, Hosoda A, Yoshikawa A, Tsuda Y, Okada Y, Lee E. The structure-activity relationship of various YO compounds, novel plasmin inhibitors, in the apoptosis induction. Biochim Biophys Acta. 2004 Nov 1;1674(3):291-8. PubMed PMID: 15541298.

16: Szende B, Okada Y, Tsuda Y, Horvath A, Bökönyi G, Okamoto S, Wanaka K, Kéri G. A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. In Vivo. 2002 Sep-Oct;16(5):281-6. PubMed PMID: 12494864.

17: Lee E, Enomoto R, Takemura K, Tsuda Y, Okada Y. A selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(O-picolyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis. Biochem Pharmacol. 2002 Apr 1;63(7):1315-23. PubMed PMID: 11960608.

18: Okada Y, Tsuda Y, Wanaka K, Tada M, Okamoto U, Okamoto S, Hijikata-Okunomiya A, Bokonyi G, Szende B, Keri G. Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and HT29 cell lines. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2217-21. PubMed PMID: 11012033.

19: Yonei T, Watarai S, Okada Y, Yasuda T, Tsuji T. Increased urinary excretion of non-albumin antigen detected with YO-2, a novel monoclonal antibody, in diabetic patients. Acta Med Okayama. 1995 Jun;49(3):153-9. PubMed PMID: 7676846.

20: Johnson JA, Hayward JJ, Kornguth SE, Siegel FL. Effects of hyperbilirubinaemia on glutathione S-transferase isoenzymes in cerebellar cortex of the Gunn rat. Biochem J. 1993 Apr 15;291 ( Pt 2):453-61. PubMed PMID: 8484726; PubMed Central PMCID: PMC1132547.